Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study

Cancer Research

Volumn 66, Issue 2, 2006, Pages 1234-1240

  Bettuzzi, Saverio ^a   Brausi, Maurizio ^b   Rizzi, Federica ^a   Castagnetti, Giovanni ^b   Peracchia, Giancarlo ^b   Corti, Arnaldo ^c  

^a UNIVERSITY OF PARMA   (Italy)

^b Nuovo Ospedale S Agostino   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CATECHIN; EPICATECHIN; EPICATECHIN 3 GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER INHIBITION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRECANCER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; QUALITY OF LIFE; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINARY TRACT DISEASE;

ADMINISTRATION, ORAL; AGED; CATECHIN; CHEMOPREVENTION; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TEA;

EID: 31544473720     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1145     Document Type: Article

References (30)

1. Nelson WG, De-Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
2. Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004;108:130-5.
3. Liao S, Kao YH, Hiipakka RA. Green tea: biochemical and biological basis for health benefits. Vitam Horm 2001;62:61-94.
4. Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 1995;96:239-43.
5. Kao YH, Hiipakka RA, Liao S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. Endocrinology 2000;141:980-7.
6. Liao S. Hiipakka RA. Selective inhibition of steroid 5α-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 1995;214:833-8.
7. Hiipakka RA, Zhang HZ, Dai W, Dai Q, Liao S. Structure-activity relationships for inhibition of human 5α-reductases by polyphenols. Biochem Pharmacol 2002; 63:1165-76.
8. Caporali A, Davalli P, Astancolle S, et al. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004;25:2217-24.
9. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56:4096-102.
10. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55: 219-37.
11. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 2001;98:10350-5.
12. Bettuzzi S, Hiipakka RA, Gilna P, Liao ST. Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulphated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem J 1989;257:293-6.
13. Bettuzzi S, Davalli P, Astancolle S, et al. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 2000; 60:28-34.
14. Scaltriti M, Brausi M, Amorosi A, et al. Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 2004; 108:123-30.
15. Bettuzzi S, Scorcioni F, Astancolle S, Davalli P, Scaltriti M, Corti A. Clusterin (SGP-2) transient over-expression decreases proliferation rate of SV40-immortalized human prostate epithelial cells by slowing down cell cycle progression. Oncogene 2002;21:4328-34.
16. Scaltriti M, Bettuzzi S, Sharrard RM, Caporali A, Caccamo AE, Maitland NJ. Clusterin overexpression in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br J Cancer 2004;91:1842-50.
17. Caccamo AE, Scaltriti M, Caporali A, et al. Cell detachment and apoptosis induction of immortalized human prostate epithelial cells are associated with early accumulation of a 45 kDa nuclear isoform of clusterin. Biochem J 2004;382:157-68.
18. Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S. Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res 2004; 64:6174-82.
19. Caccamo AE, Scaltriti M, Caporali A, et al. Ca(2+) depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ 2005;12:101-4.
20. Moyers SB, Kumar NB. Green tea polyphenols and cancer chemoprevention: multiple mechanisms and endpoints for phase II trials. Nutr Rev 2004;62:204-11.
21. Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004;17:360-79.
22. Bishara T, Ramnani DM, Epstein JI. High-grade prostatic intraepithelial neoplasia on needle biopsy: risk of cancer on repeat biopsy related to number of involved cores and morphologic pattern. Am J Surg Pathol 2004;28:629-33.
23. Kronz JD, Allan CH, Shaikh AA, Epstein JI. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 2001;25:1079-85.
24. O'Leary MP. Quality of life and sexuality: methodological aspects. Eur Urol 2001;40 Suppl 43:13-48.
25. Grumann M, Schlag PM. Assessment of quality of life in cancer patients: complexity, criticism, challenges. Onkologie 2001;24:10-5.
26. Steiner MS. High-grade prostatic intraepithelial neoplasia and prostate cancer risk reduction. World J Urol 2003;21:15-20.
27. Denis LJ. Future implications for the management of benign prostatic hyperplasia. Eur Urol 1994;25 Suppl 21: 29-34.
28. Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003;9: 3312-9.
29. Ahn WS, Yoo J, Huh SW, et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev 2003;12:383-90.
30. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.